“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

05 July 2019
Pharma

Visiongain has launched a new pharma report Global Influenza Vaccines Market Outlook 2019-2029: Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments for Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other.

Growth is mainly driven by the ageing population and the increasing prevalence of health problems associated with age. This will drive the demand from both the developing and the developed world for influenza vaccines. The emerging markets will benefit from improved healthcare systems and in turn they will add to the demand of the influenza vaccines owing to their high birth rates. Furthermore, research and development will lead to continuous innovation within the vaccines industry. Advancements will be made in the delivery and target technology used in the influenza vaccines.

The lead analyst of the report commented "The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market. There is an increasing focus to identify the research gaps and unmet needs of the influenza vaccines market. This includes vaccine technology that provides wider coverage and easier access and administration of the influenza vaccines. This breeds a strong platform for both start-ups and larger pharmaceutical companies to create newer influenza vaccine technology that is not already on the market. This prevents stagnation within the market and will help drive the growth of the influenza vaccines market."

Leading companies featured in the report include Sanofi Pasteur, Seqirus, GlaxoSmithKline (GSK), AstraZeneca, Abbott Laboratories, Sinovac Biotech and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“The worldwide industry for silicone additives is likely to experience important development”, says Visiongain

It is anticipated that the benefits of silicone additives such as elevated drop, marine strength, and leveling & humidity regulate will boost their use in cosmetics, coatings, and paint applications.

16 October 2019

Read

“Global nephrology and urology devices market is anticipated to surpass USD 39 Bn by 2030”, says Visiongain

Nephrology is a field of medicine that is concerned with studying kidney function, treating kidney issues, and therapy for renal substitute.

16 October 2019

Read

“The global Nasal Drug Delivery Technology market is anticipated to surpass USD 80 Billion by 2030”, says Visiongain

Asia Pacific region is anticipated to experience the highest growth in terms of CAGR over the forecast period owing to the availability of effective treatment methods, high unmet clinical needs, rising disposable income levels, and increasing awareness about these products.

16 October 2019

Read

“The global Myeloproliferative Disorders Drugs market is anticipated to surpass USD 11 Bn by 2030”, says Visiongain

The emergence of a new therapy for myeloproliferative disorders and the accessibility of new drugs is anticipated to drive the market drugs for myeloproliferative disorders.

16 October 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever